Related Experiment Videos
Large-scale processing of recombinant retroviruses for gene therapy
S T Andreadis1, C M Roth, J M Le Doux
1Center for Engineering in Medicine and Surgical Services, Massachusetts General Hospital, Harvard Medical School, Shriners Burns Hospital, Boston, Massachusetts 02114, USA.
Biotechnology Progress
|February 6, 1999
Summary
Large-scale production of retroviral vectors for gene therapy faces challenges. New technologies are needed for efficient manufacturing, purification, and storage to advance clinical applications.
Area of Science:
- Biotechnology
- Molecular Biology
- Gene Therapy
Background:
- Gene therapy offers potential for treating inherited and acquired diseases.
- Recombinant retroviruses are the primary vectors in current gene therapy clinical trials.
- Existing manufacturing processes for recombinant proteins may not fully apply to retroviral particles.
Purpose of the Study:
- To review critical concerns in the large-scale production and processing of retroviral particles for gene therapy.
- To identify challenges related to the instability, sensitivity, complexity, and size of retroviral vectors.
- To examine strategies for optimizing production, concentration, purification, formulation, and storage of retroviral vectors.
Main Methods:
- Review of current manufacturing and processing techniques for recombinant retroviruses.
- Analysis of challenges specific to retroviral particle characteristics.
- Examination of potential new technologies for retroviral vector production.
Main Results:
- Retroviral particles present unique challenges due to their instability, sensitivity, complexity, and size.
- Current manufacturing processes require adaptation and new technologies for efficient retroviral vector production.
- Key areas for development include production, concentration, purification, formulation, and storage.
Conclusions:
- Developing robust, large-scale manufacturing processes for recombinant retroviruses is crucial for gene therapy.
- Addressing production and processing challenges will enhance gene transfer efficiencies.
- Advancements in retroviral vector manufacturing will significantly impact the clinical implementation of gene therapy.